Business Advisory services                  Life Sciences Consulting                  Product Development                  ANDAs                  FTFs                  505 b 2 a                  Late Stage Assets                  Phase-II Trials                  Marketing Authorizationís                  Dossiers                  Site Transfers                  Scale ups                   Tail End Brands                  Technologies and Know-how                  Project Management                   Business Excellence & Six Sigma
Garphi was commissioned by an investment company to develop a strategy for transforming a low-margin generics company into a higher-margin branded pharmaceutical marketer in Eastern Europe.
Garphi developed a strategic plan outlining the steps necessary to transform the company, involving the in-licensing and acquisition of established products portfolio and the divestment of low-margin operations. Post the approval of the strategic plan, Garphi was requested to assist the plan roll-out . Garphi identified promising assets whose commercial rights were then negotiated on behalf of the client.Garphiís team also assisted in the transfer of manufacturing to the clientís plants.
Garphiís collaboration with this client lasted little over 30 months, with a total of 18 products in-licensed from five different companies followed by successful site transfers. The new portfolio of products enabled the company to grow its branded business from 23% of turnover to 55 % in over 3 years. Over the same interval, the company moved in its IMS rankings by 9 positions based on the sales reported in its home country. Eventually, the Investment firm now wishes to engageGarphi for selling the company to a strategic investor.